Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A Markov model study based on two longitudinal observational studies

Rheumatology (United Kingdom)

Volumn 54, Issue 7, 2015, Pages 1226-1235

  Kvamme, Maria K ^a,b   Lie, Elisabeth ^a   Uhlig, Till ^a   Moger, Tron A ^a   Kvien, Tore K ^a   Kristiansen, Ivar S ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

Author keywords

Antirheumatic agent; Arthritis; Cost effectiveness; Markov chain; Receptors; Rheumatoid; Tumour necrosis factor; Type I

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH STATUS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS;

EID: 84936888997     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu460     Document Type: Article

References (45)

1. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
2. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT study Group. Lancet 1999;354:1932-9.
3. Breedveld F, Weisman M, Kavanaugh A et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
4. Knevel R, Schoels M, Huizinga TWJ et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:987-94.
5. Singh JA, Christensen R, Wells GA et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;4:CD007848.
6. Kvamme MK, Lie E, Kvien TK, Kristiansen IS. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry. Rheumatology 2012;51:1618-27.
7. Fautrel B, Verstappen SM, Boonen A. Economic consequences and potential benefits. Best Pract Res Clin Rheumatol 2011;25:607-24.
8. Van den Hout WB, Goekoop-Ruiterman YPM, Allaart CF et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Care Res 2009;61:291-9.
9. Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
10. Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73: 492-509.
11. Schoels M, Wong J, Scott DL et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:995-1003.
12. Wong JB, Singh G, Kavanaugh A. Estimating the costeffectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.
13. Kobelt G, Jönsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42:326-35.
14. Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005;64: 1174-9.
15. Lekander I, Borgström F, Svarvar P. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden. Int J Technol Assess Health Care 2010;26:54-61.
16. Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumor necrosis factor in rheumatoid arthritis. Health Technol Assess 2004;8:iii, 1-91.
17. Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004; 43:62-72.
18. Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995-1002.
19. Brennan A, Bansback N, Nixon R et al. Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology 2007;46: 1345-54.
20. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis 1987;40: 593-600.
21. van der Velde G, Pham B, Machado M et al. Costeffectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res 2011;63: 65-78.
22. Tosh J, Brennan A, Wailoo A, Bansback N. The Sheffield rheumatoid arthritis health economic model. Rheumatology 2011;50:iv26-iv31.
23. Hernández Alava M, Wailoo A, Wolfe F, Michaud K. The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis. Rheumatology 2013;52: 944-50.
24. Kvien TK, Heiberg MS, Lie E et al. A Norwegian DMARD register: Prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005;23:s188-94.
25. Kvien TK, Glennas A, Knudsrod OG et al. The prevalence and severity of rheumatoid arthritis in Oslo. Results from a county register and population survey. Scand J Rheumatol 1997;26:412-8.
26. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
27. Zink A, Askling J, Dixon WG et al. European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 2009;68:1240-6.
28. Lie E, van der Heijde D, Uhlig T et al. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register. Ann Rheum Dis 2011;70:2103-10.
29. Uhlig T, Heiberg T, Mowinckel P, Kvien TK. Rheumatoid arthritis is milder in the new millennium: health status in patients with rheumatoid arthritis 1994-2004. Ann Rheum Dis 2008;67:1710-5.
30. Austad C, Kvien TK, Olsen IC, Uhlig T. Health status has improved more in women than in men with rheumatoid arthritis from 1994 to 2009: results from the Oslo rheumatoid arthritis register. Ann Rheum Dis 2013. Advance Access published 15 October 2013. doi: 10.1136/annrheumdis-2013-204014.
31. Ware JE, Sherbourne CD. The MOS 36-ltem short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992;30:473-83.
32. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004;13:873-85.
33. Norwegian Directorate of Health. Economic evaluation of healthcare interventions: a guide. Oslo: Norwegian Directorate of Health, 2012.
34. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.
35. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008;26:35-61.
36. Brazier J, Ratcliffe J, Salomon J, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. New York: Oxford University Press, 2007.
37. Briggs A, Claxton K, Schulper M. Decision modelling for health economic evaluation. Oxford, UK: Oxford University Press, 2006.
38. Sælensminde K. Health effects in economic analyses. Oslo. The Norwegian Directorate of Health, 2007.
39. Welsing PMJ, Severens JL, Hartman M, van Riel PLCM, Laan RFJM. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factorblocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. Arthritis Rheum 2004;51: 964-73.
40. Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology 2005;44:1169-75.
41. Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum 2000;43:2751-61.
42. Scott DL, Pugner K, Kaarela K et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000;39:122-32.
43. Stevenson MD, Archer R, Tosh J et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying anti-rheumatic drugs and after the failure of conventional disease-modifying anti-rhuematic drugs only: systematic review and economic evaluation. Health Technol Assess 2013;1-736.
44. Upton G, Cook I. A dictionary of statistics. 2nd rev. edn. Oxford UK: Oxford University Press, 2008.
45. Gregersen F. The impact of ageing on health care expenditures: a study of steepening. The Eur J Health Economics 2013. Advance Access published 24 November 2013, doi:10.1007/s10198-013-0541-9.